Literature DB >> 20709616

Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma.

Lorenzo Richiardi1, Laura De Marco, Anna Gillio-Tos, Franco Merletti, Valentina Fiano, Domenico Palli, Giovanna Masala, Claudia Agnoli, Giovanna Tagliabue, Salvatore Panico, Amalia Mattiello, Rosario Tumino, Graziella Frasca, Paolo Vineis, Carlotta Sacerdote.   

Abstract

Hepatitis C virus (HCV) and Epstein-Barr virus (EBV) have been repeatedly associated with risk of non-Hodgkin's lymphoma (NHL) in studies focusing on serological evidence of infection. We investigated NHL risk in association with detection of HCV-RNA or EBV-DNA in the peripheral blood mononuclear cells (PBMC). The study involved 91 NHL cases and 182 controls nested in the Italian branch of the EPIC (European Prospective Investigation of Cancer and nutrition) cohort, which obtained blood samples from 47,749 healthy volunteers between 1993 and 1998 in 5 Italian cities. NHL cases were identified until June 2005 through linkage with records of the Cancer, Mortality, and Hospital Discharge Registries. For all study subjects, we performed viral genome analyses on DNA and RNA extracted from buffy-coats and analysed EBV and HCV antibodies. The odds ratios (ORs) of NHL were 1.2 (95% confidence intervals: 0.4-3.8; 5 exposed cases) for PBMC HCV infection and 1.2 (0.7-2.3; 24 exposed cases) for PBMC EBV infection. Similar OR estimates were found for detection of EBV and HCV antibodies. These null results, although based on a relatively small sample size, suggest that persistent EBV and HCV infection in the PBMC is not a stronger predictor of NHL risk than serological evidence of infection.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709616     DOI: 10.1016/j.canep.2010.07.014

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  8 in total

1.  Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort.

Authors:  Anneclaire J De Roos; Otoniel Martínez-Maza; Keith R Jerome; Dana K Mirick; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Kerstin L Edlefsen; Andrea Z Lacroix
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-24       Impact factor: 4.254

Review 2.  Hepatitis C virus: A time for decisions. Who should be treated and when?

Authors:  Bashar M Attar; David H Van Thiel
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Authors:  Anna E Coghill; Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2014-08-28       Impact factor: 4.897

4.  Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.

Authors:  Mohammed A Sarhan; Annie Y Chen; Tomasz I Michalak
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

5.  Hepatitis C virus infection is a risk factor for non-Hodgkin lymphoma: A MOOSE-compliant meta-analysis.

Authors:  Xiaofeng Zhu; Li Jing; Xiaoming Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

6.  Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease.

Authors:  Laura De Marco; Paola Manzini; Morena Trevisan; Anna Gillio-Tos; Franca Danielle; Cinzia Balloco; Alessandra Pizzi; Eleonora De Filippo; Sergio D'Antico; Beatrice Violante; Adriano Valfrè; Franco Curti; Franco Merletti; Lorenzo Richiardi
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

7.  Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis.

Authors:  Hossein Keyvani; Farah Bokharaei-Salim; Seyed Hamidreza Monavari; Maryam Esghaei; Mohssen Nassiri Toosi; Shahin Fakhim; Zohreh Azita Sadigh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-08-05       Impact factor: 0.660

Review 8.  A New Twist to a Chronic HCV Infection: Occult Hepatitis C.

Authors:  Bashar M Attar; David Van Thiel
Journal:  Gastroenterol Res Pract       Date:  2015-06-24       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.